Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

CU Anschutz clinical trial finds GLP-1s help curb alcohol use disorder

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at 9news.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

A CU Anschutz clinical trial led by Dr. Joseph Schacht found that the semaglutide pill, used for diabetes and weight loss, significantly reduced heavy alcohol consumption, cravings, and related problems among heavy drinkers.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You now have a new pharmaceutical option to explore for treating alcohol use disorder leveraging semaglutide’s unexpected effect on cravings. This opens a drug repurposing path that could reduce patient relapse and expand your treatment portfolio.

◆ Coverage

2 sources · 10 Aug 2026

◆ Related on Wire

◆ Topics

Healthclinical-trialalcohol-use-disordersemaglutidemental-healthpharmaceuticals